Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors.

What was studied

This phase 3 study tested denecimig, also called Mim8. It was in children aged 1 to 11 years with hemophilia A. Some had FVIII inhibitors. Children got weekly shots under the skin for 26 weeks. Then caregivers chose weekly or monthly dosing for 26 more weeks. The main goal was adverse events.

What they found

All 70 children finished both parts. 38 stayed weekly and 32 moved to monthly. All adverse events were mild or moderate. None led to stopping. No clot events were seen. Most children had no treated bleeds. All 10 target joints resolved. Caregivers said treatment was less of a burden. They also said physical function was better.

What it means for patients

The team says denecimig was well tolerated over 52 weeks. They saw no safety concerns. They say it gave strong bleed protection. They say it cut the treatment burden and improved quality of life.

Why it is not certain yet

The abstract names no comparison group. In part 2, caregivers chose weekly or monthly dosing. So those groups were not set by chance. The abstract covers 52 weeks.

Source

Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors.

We restate facts from the source record in our own words. The original wording belongs to its publisher.